Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.70 +0.4%	$6.55	$2.33 ▼ $39.00	$2.06M	0.88	66,661 shs	71,785 shs
PKBO Peak Bio	$0.02	$0.05	$0.00 ▼ $0.26	$520K	1.75	8,940 shs	66,140 shs
SXTP 60 Degrees Pharmaceuticals	$1.26 -3.1%	$1.77	$1.24 ▼ $12.70	$5.34M	2.71	114,890 shs	33,058 shs
UPC Universe Pharmaceuticals	$3.50 +2.0%	$3.72	$2.51 ▼ $2,064.00	$1.97M	1.43	266,154 shs	17,325 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+0.37%	+1.89%	-68.05%	-70.46%	-93.15%
PKBO Peak Bio	0.00%	0.00%	0.00%	0.00%	+800.00%
SXTP 60 Degrees Pharmaceuticals	-3.08%	-4.55%	-5.97%	-37.31%	-86.81%
UPC Universe Pharmaceuticals	+0.57%	-1.82%	-8.62%	-25.05%	-99.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.4161 of 5 stars	3.5	0.0	0.0	0.0	2.1	0.0	0.0
PKBO Peak Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.3906 of 5 stars	3.3	4.0	0.0	0.0	0.0	2.5	0.6
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	10,085.19% Upside
PKBO Peak Bio	0.00	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	455.56% Upside
UPC Universe Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PKBO, AIM, UPC, and SXTP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/12/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$121K	17.05	N/A	N/A	$0.20 per share	13.50
PKBO Peak Bio	$370K	1.41	N/A	N/A	($0.90) per share	-0.03
SXTP 60 Degrees Pharmaceuticals	$300K	17.22	N/A	N/A	($1.76) per share	-0.72
UPC Universe Pharmaceuticals	$19.29M	0.10	N/A	N/A	$163.50 per share	0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.68	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
PKBO Peak Bio	-$12.83M	-$0.16	N/A	∞	N/A	N/A	N/A	-179.31%	N/A
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-976.86%	N/A	-133.88%	N/A
UPC Universe Pharmaceuticals	-$6.16M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest PKBO, AIM, UPC, and SXTP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	SXTP 60 Degrees Pharmaceuticals	-$1.24	-$1.25	-$0.01	-$1.25	$0.32 million	$0.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
PKBO Peak Bio	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
PKBO Peak Bio	N/A	0.07	0.06
SXTP 60 Degrees Pharmaceuticals	N/A	2.27	1.80
UPC Universe Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
PKBO Peak Bio	N/A
SXTP 60 Degrees Pharmaceuticals	7.96%
UPC Universe Pharmaceuticals	0.18%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
PKBO Peak Bio	19.90%
SXTP 60 Degrees Pharmaceuticals	10.27%
UPC Universe Pharmaceuticals	57.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
PKBO Peak Bio	3	23.13 million	18.52 million	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	4.10 million	1.32 million	Not Optionable
UPC Universe Pharmaceuticals	220	563,000	731,000	Not Optionable

PKBO, AIM, UPC, and SXTP Headlines

Recent News About These Companies

Universe Pharmaceuticals Inc. (UPC) Stock Price Today - WSJ

August 7, 2025 | wsj.com

Pharma Playbook: What Practitioners Can Learn from Early UPC Litigation

May 14, 2025 | ipwatchdog.comI

Universe Pharmaceuticals Reports Full Year 2024 Earnings

May 3, 2025 | finance.yahoo.com

Universe Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025

March 20, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | gurufocus.com

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | investing.com

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | globenewswire.com

Universe Pharmaceuticals Approves Share Consolidation at Extraordinary Meeting

March 11, 2025 | tipranks.com

Universe Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report Filing

February 25, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

February 25, 2025 | globenewswire.com

Universe Pharmaceuticals proposes revised share consolidation

February 11, 2025 | msn.com

Universe Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest Report

February 10, 2025 | benzinga.com

Universe Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

February 6, 2025 | finanznachrichten.de

UPC’s Unexpected Plunge: What’s Next?

February 5, 2025 | bovnews.comB

Universe Pharmaceuticals gets Nasdaq delisting notice

February 4, 2025 | markets.businessinsider.com

Universe Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share Price

February 3, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

February 3, 2025 | globenewswire.com

Universe Pharmaceuticals announces shareholder meeting

January 30, 2025 | msn.com

Universe Pharmaceuticals stock hits 52-week low at $0.48 amid steep decline

January 29, 2025 | msn.com

Universe Pharmaceuticals Inc (UPC) Stock: A Deeper Look at Its True Potential

December 29, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PKBO, AIM, UPC, and SXTP Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.70 +0.01 (+0.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.67 -0.03 (-1.11%)

As of 08/22/2025 07:12 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Peak Bio NASDAQ:PKBO

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.26 -0.04 (-3.08%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.28 +0.02 (+1.59%)

As of 08/22/2025 07:38 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Universe Pharmaceuticals NYSE:UPC

$3.50 +0.07 (+2.04%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$3.58 +0.08 (+2.40%)

As of 08/22/2025 04:31 PM Eastern

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time